Ivermectin vs. Thiabendazole for Strongyloidiasis Treatment
Author Information
Author(s): Bisoffi Zeno, Buonfrate Dora, Angheben Andrea, Boscolo Marina, Anselmi Mariella, Marocco Stefania, Monteiro Geraldo, Gobbo Maria, Bisoffi Giulia, Gobbi Federico
Primary Institution: Centre for Tropical Diseases, S. Cuore Hospital, Negrar (Verona), Italy
Hypothesis
Is ivermectin more effective and safer than thiabendazole for treating strongyloidiasis?
Conclusion
Ivermectin is better tolerated than thiabendazole, but both drugs have similar efficacy in treating strongyloidiasis.
Supporting Evidence
- Efficacy was 56.6% for ivermectin and 52.2% for thiabendazole.
- Mild to moderate side effects were observed in 20.9% of patients taking ivermectin compared to 73.1% in the thiabendazole group.
- The study included 198 patients who completed follow-up.
Takeaway
This study looked at two medicines to treat a worm infection. Both worked about the same, but one had fewer side effects.
Methodology
A phase III, randomized, open-label trial comparing ivermectin and thiabendazole in patients with strongyloidiasis.
Potential Biases
Potential bias in side effect reporting due to knowledge of the treatment received.
Limitations
The trial was not double-blind, which may have influenced side effect reporting.
Participant Demographics
Patients were male and female, older than 5 years, and weighing more than 15 kg.
Statistical Information
P-Value
0.53
Statistical Significance
p=0.53
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website